10. SEGMENT REPORTING (Tables)

12 Months Ended

Apr. 30, 2016

Segment Reporting [Abstract]

Segment information

	2016			2015			2014
Contract manufacturing services revenue	$	44,357,000		$	26,744,000		$	22,294,000
Cost of contract manufacturing services		22,966,000			15,593,000			13,110,000
Gross profit	$	21,391,000		$	11,151,000		$	9,184,000
Revenue from products in research and development	$	329,000		$	37,000		$	107,000
Research and development expense		(59,529,000	)		(42,996,000	)		(27,723,000	)
Selling, general and administrative expense		(18,551,000	)		(18,691,000	)		(17,274,000	)
Other income (expense), net		708,000			141,000			344,000
Net loss	$	(55,652,000	)	$	(50,358,000	)	$	(35,362,000	)

Customer Revenue

Customer	Geographic Location	2016		2015		2014
Halozyme Therapeutics, Inc.	U.S.		69%		79%		91%
Customer A	U.S.		26		12		–
Other customers	U.S./non-U.S.		5		9		9
Total			100%		100%		100%

Customer revenue by geographic location

		2016		2015		2014
U.S.		$	44,357,000	$	26,715,000	$	22,225,000
Non-U.S.			–		29,000		69,000
	Total	$	44,357,000	$	26,744,000	$	22,294,000

Long-lived assets

	2016		2015
Long-lived Assets, net:
Contract manufacturing services	$	22,783,000	$	12,800,000
Products in research and development		1,519,000		2,324,000
Total	$	24,302,000	$	15,124,000